Cambridge Investment Research Advisors
PSTV icon

Cambridge Investment Research Advisors’s Plus Therapeutics PSTV Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Hold
538
– – ﹤0.01% 3918
2025
Q4 		$7K Buy
538
+118
+28% +$1.78K ﹤0.01% 3806
2025
Q3 		$7K Buy
+420
New +$5.16K ﹤0.01% 3709
2019
Q3 		– Sell
-1
Closed -$5K – 2393
2019
Q2 		$5K Hold
1
– – ﹤0.01% 2193
2019
Q1 		$5K Buy
+1
New +$5.28K ﹤0.01% 2271

Other funds holding PSTV

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Cambridge Investment Research Advisors's PSTV Position: Q1 2026 in Review

Cambridge Investment Research Advisors held its Plus Therapeutics (PSTV) position steady in Q1 2026 at 538 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #3918.

Cambridge Investment Research Advisors first reported a position in PSTV in Q1 2019 and has held it in 5 quarters since. The position peaked at $7K in Q4 2025. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • Cambridge Investment Research Advisors held 538 shares of Plus Therapeutics worth $2K as of Q1 2026.
  • Cambridge Investment Research Advisors left its Plus Therapeutics share count unchanged in Q1 2026.
  • Plus Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3918 holding.
  • Cambridge Investment Research Advisors first reported a position in Plus Therapeutics in Q1 2019 and has held it in 5 quarters since.
  • Cambridge Investment Research Advisors's Plus Therapeutics position peaked at $7K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.